Patrick Sharma

Cooley advised Wugen, a clinical-stage biotechnology company pioneering the next generation of allogeneic, off-the-shelf chimeric antigen receptor T-cell (CAR-T) therapies, on its $115 million Series C financing.

Cooley advised TBO, a leading global travel distribution platform, on its agreement to acquire Classic Vacations from Arizona-based investment firm, the Najafi Companies.

Cooley advised Contentsquare, an all-in-one experience intelligence platform, on its definitive agreement to acquire Loris AI, a conversation intelligence platform, to give business leaders a deeper, more accurate view of the full customer journey – from click to conversation.

Cooley advised MapLight Therapeutics, a clinical-stage biopharmaceutical company developing targeted, novel therapies for patients with central nervous system disorders, on its oversubscribed $372.5 million Series D financing.

Cooley advised Hengrui Pharma, a global pharmaceutical company, on its up to $12.5 billion agreement with GSK to develop up to 12 medicines to complement GSKs extensive respiratory, immunology and inflammation (RI&I) and oncology pipeline.